This March is ending with a sudden sad farewell to Josep Baselga, a major global touchstone from the BioRegion in oncological research and the treatment of breast cancer and one of the prime driving forces behind the concept of personalized medicine.
This February has been marked, to a large extent, by the European recovery funds that are keeping a close eye on the BioRegion. And in hospitals, activity continues to keep up the pace of research.
During January the vaccines from Pfizer and Moderna have been administrated. In the BioRegion, the year got off to a strong start for a good number of startups, which have received funding, and for some local pharmaceutical corporations.
